"I had surgery and I even went through radiation—so why did it come back?" Families of glioblastoma patients face this devastating question time and again.
Glioblastoma is the most aggressive type of glioma, a category of brain cancer that originates in glial cells. Classified as a Grade 4 malignancy by the World Health Organization (WHO), it carries a dismal five-year survival rate of roughly 7%, cementing its status as one of the solid tumors with the poorest clinical prognoses. Despite decades of intensive scientific research, patient survival outcomes have barely budged.
The barriers to effective treatment are multifaceted. Glioblastoma cells do not form clean, isolated masses; instead, they grow by burrowing finger-like projections deep into healthy brain tissue, making complete surgical resection nearly impossible. Chemotherapy options are similarly limited, as the protective blood-brain barrier blocks most standard oncology agents from entering the brain. Even when a treatment successfully shrinks the primary tumor, surviving brain tumor stem cells (BTSCs) remain behind, acting as the quiet seeds of future recurrence.
A breakthrough study led by Associate Professor Arezu Jahani-Asl of the Department of Cellular and Molecular Medicine at the University of Ottawa Faculty of Medicine has uncovered a critical piece of this molecular puzzle. The research team discovered that a channel protein known as CLIC1 teams up with a receptor protein called OSMR to keep glioblastoma cells alive under stress. Their findings, published in the May 23 issue of the international medical journal Signal Transduction and Targeted Therapy, map this hidden partnership for the first time, explaining how it fuels tumor growth and drives treatment resistance.
How the Two Proteins Orchestrate Treatment Resistance
To understand why traditional therapies fail, researchers have long focused on individual cellular pathways. In glioblastoma, the oncostatin M receptor (OSMR) is well-established as a central coordinator of tumor progression. It integrates microenvironmental signals, shifts cancer cells into highly aggressive states, elevates resistance to radiation therapy, and upregulates energy production within brain tumor stem cells. However, how a single receptor managed to orchestrate all of these survival mechanisms simultaneously had remained a mystery.
Using an advanced protein-interaction screening technique known as Mammalian Membrane Two-Hybrid High-Throughput Screening (MaMTH-HTS), Jahani-Asl's team systematically mapped the network of proteins that physically interact with OSMR. The analysis identified chloride intracellular channel 1 (CLIC1) as a vital partner.
Under normal physiological conditions, CLIC1 resides within cells or integrates into the plasma membrane to regulate ionic flow. In glioblastoma, however, its function alters dramatically. It acts as a molecular switchboard, relaying the specific downstream signals that allow cancer cells to withstand therapeutic stress and infiltrate surrounding brain architecture. The study demonstrated that OSMR and CLIC1 work in tandem, creating a self-reinforcing, bidirectional feedback loop.
"Glioblastoma activates multiple survival pathways at the same time, which is why existing targeted treatments have repeatedly hit a wall," Jahani-Asl explained. "The OSMR–CLIC1 axis behaves like a central control node that influences several tumor-promoting processes at once. By cutting off this connection, we may be able to disable multiple resistance mechanisms simultaneously."
Halting Tumor Infiltration with Targeted Antibodies
To test this hypothesis, the researchers used CRISPR gene-editing technology to delete the CLIC1 gene in patient-derived brain tumor stem cells. The results were immediate: removing CLIC1 severed the link between OSMR and a common mutant receptor, EGFRvIII, while simultaneously suppressing STAT3—a core transcription factor that drives cancer cell proliferation. This intervention slowed glioblastoma progression noticeably in preclinical models.
The impact extended beyond merely slowing down cell division. When these modified tumor stem cells were implanted into animal models, tumor growth was profoundly suppressed. Collaborating researchers at the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto noted that eliminating CLIC1 fundamentally stripped the glioblastoma cells of their ability to migrate and invade healthy tissue. Because invasive migration into surrounding brain tissue is the primary reason these tumors recur after surgery, neutralizing CLIC1 directly dismantles the mechanism responsible for seeding secondary tumors.
Because gene editing cannot be applied directly to human patients, the research team developed a practical therapeutic alternative: a monoclonal antibody named tmCLIC1omab. This specialized drug was designed to target and block only the specific configuration of CLIC1 exposed on the outer cell membrane of the tumor.
When tested in both cellular and in vivo mouse models, the antibody achieved the same therapeutic success as gene deletion. It successfully disrupted oncogenic signaling, impaired the self-renewal capacity of brain tumor stem cells, and halted progression. Because monoclonal antibodies are already widely utilized to treat breast and blood cancers, identifying a targetable membrane configuration of CLIC1 provides a clear, practical roadmap for drug development.
"When you study glioblastoma, you see firsthand how quickly the disease progresses and how it devastates not only patients but entire families," Jahani-Asl said. "That difficult reality pushes our laboratory toward finding genuine breakthroughs."
Moving forward, the research team plans to validate these findings across various molecular subtypes of glioblastoma to determine which patient cohorts will respond best to therapies targeting the OSMR–CLIC1 axis. They also intend to evaluate the safety and efficacy of combining the tmCLIC1omab antibody with the current standard of care, including surgery, radiation, and temozolomide chemotherapy.
The scale of the disease underscores the urgency of this research. According to data from the Seoul National University Cancer Research Institute, approximately 630 people in South Korea are newly diagnosed with glioblastoma each year. More broadly, the Korea Central Cancer Registry reported 2,011 cases of malignant primary brain tumors in 2023 alone. Translating these laboratory insights into an approved clinical treatment will require rigorous human clinical trials, a process that typically takes several years. Nevertheless, for a disease where the five-year survival rate has remained stagnant for decades, identifying the precise molecular accomplices behind tumor recurrence offers a critical path forward.
